Ways into Understanding HIF Inhibition
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
Hypoxia is a key characteristic of tumor tissue. Cancer cells adapt to low oxygen by activating hypoxia-inducible factors (HIFs), ensuring their survival and continued growth despite this hostile environment. Therefore, the inhibition of HIFs and their target genes is a promising and emerging field of cancer research. Several drug candidates target protein–protein interactions or transcription mechanisms of the HIF pathway in order to interfere with activation of this pathway, which is deregulated in a wide range of solid and liquid cancers. Although some inhibitors are already in clinical trials, open questions remain with respect to their modes of action. New imaging technologies using luminescent and fluorescent methods or nanobodies to complement widely used approaches such as chromatin immunoprecipitation may help to answer some of these questions. In this review, we aim to summarize current inhibitor classes targeting the HIF pathway and to provide an overview of in vitro and in vivo techniques that could improve the understanding of inhibitor mechanisms. Unravelling the distinct principles regarding how inhibitors work is an indispensable step for efficient clinical applications and safety of anticancer compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909353106 · Cited by 451
RetractedNaturally occurring antibodies devoid of light chains
Hamers-Casterman, C., Atarhouch, T., Muyldermans, S., Robinson, G., Hammers, C., Songa, E. B., Bendahman, N., & Hammers, R. (1993) · Nature · doi:10.1038/363446a0 · Cited by 3,241
Mitochondrial reactive oxygen species trigger hypoxia-induced transcription
Chandel, N. S., Maltepe, E., Goldwasser, E., Mathieu, C. E., Simon, M. C., & Schumacker, P. T. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11715 · Cited by 1,926
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514
Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation
Hu, C.-J., Wang, L.-Y., Chodosh, L. A., Keith, B., & Simon, M. C. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.24.9361-9374.2003 · Cited by 1,386
Talks, K. L., Turley, H., Gatter, K. C., Maxwell, P. H., Pugh, C. W., Ratcliffe, P. J., & Harris, A. L. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64554-3 · Cited by 1,312
Hypoxia-Inducible Factors, Stem Cells, and Cancer
Keith, B., & Simon, M. C. (2007) · Cell · doi:10.1016/j.cell.2007.04.019 · Cited by 1,179
HDAC6 Regulates Hsp90 Acetylation and Chaperone-Dependent Activation of Glucocorticoid Receptor
Kovacs, J. J., Murphy, P. J. M., Gaillard, S., Zhao, X., Wu, J.-T., Nicchitta, C. V., Yoshida, M., Toft, D. O., Pratt, W. B., & Yao, T.-P. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.021 · Cited by 1,153 · cited 1×
“Likewise, panobinostat (LBH589), developed for solid and hematologic cancers, acts as a histone deacetylase (HDAC) inhibitor and disrupts the Hsp90/HDAC6 complex [51].”
BackgroundWenger, R. H. (2002) · The FASEB Journal · doi:10.1096/fj.01-0944rev · Cited by 1,135 · cited 4×
“is regulated by the abundance and binding affinity of the α subunits to regulate a variety of genes in physiology and pathophysiology [3,17].”
BackgroundInfluentialEma, M., Taya, S., Yokotani, N., Sogawa, K., Matsuda, Y., & Fujii-Kuriyama, Y. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4273 · Cited by 1,016 · cited 1×
“HIF-1α/HIF-2α are highly homologous, with approximately 70% identity in their amino acid sequence and they function in a similar manner [4].”
Background
Research works printed but not linked: 93
- Semenza, 1992, A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation, Mol. Cell. Biol., 12, 5447
- Greijer, 2005, Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1), J. Pathol. A J. Pathol. Soc. G. B. Irel., 206, 291
- Yamashita, 2008, Abnormal heart development and lung remodeling in mice lacking the hypoxia-inducible factor-related basic helix-loop-helix PAS protein NEPAS, Mol. Cell. Biol., 28, 1285, 10.1128/MCB.01332-07 · DOI · Paper page
- Tanaka, 2009, The human HIF (hypoxia-inducible factor)-3 α gene is a HIF-1 target gene and may modulate hypoxic gene induction, Biochem. J., 424, 143, 10.1042/BJ20090120 · DOI · Paper page
- Zhang, 2014, Hypoxia-inducible factor 3 is an oxygen-dependent transcription activator and regulates a distinct transcriptional response to hypoxia, Cell Rep., 6, 1110, 10.1016/j.celrep.2014.02.011 · DOI · Paper page
- Schofield, 2005, Signalling hypoxia by HIF hydroxylases, Biochem. Biophys. Res. Commun., 338, 617, 10.1016/j.bbrc.2005.08.111 · DOI · Paper page
- Fandrey, 2006, Regulating cellular oxygen sensing by hydroxylation, Cardiovasc. Res., 71, 642, 10.1016/j.cardiores.2006.05.005 · DOI · Paper page
- Bruick, 2001, A conserved family of prolyl-4-hydroxylases that modify HIF, Science, 294, 1337, 10.1126/science.1066373 · DOI · Paper page
- Watts, 2019, Inflammation and hypoxia: HIF and PHD isoform selectivity, Trends Mol. Med., 25, 33, 10.1016/j.molmed.2018.10.006 · DOI · Paper page
- Maxwell, 1993, Inducible operation of the erythropoietin 3’ enhancer in multiple cell lines: Evidence for a widespread oxygen-sensing mechanism, Proc. Natl. Acad. Sci. USA, 90, 2423, 10.1073/pnas.90.6.2423 · DOI · Paper page
- Paltoglou, 2007, HIF-1 α and EPAS ubiquitination mediated by the VHL tumour suppressor involves flexibility in the ubiquitination mechanism, similar to other RING E3 ligases, Oncogene, 26, 604, 10.1038/sj.onc.1209818 · DOI
- Wang, 1995, Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension, Proc. Natl. Acad. Sci. USA, 92, 5510, 10.1073/pnas.92.12.5510 · DOI · Paper page
- Hanahan, 2011, Hallmarks of cancer: The next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
- Haddad, 2001, A non-hypoxic, ROS-sensitive pathway mediates TNF-α-dependent regulation of HIF-1α, FEBS Lett., 505, 269, 10.1016/S0014-5793(01)02833-2 · DOI · Paper page
- Acker, 2006, The good, the bad and the ugly in oxygen-sensing: ROS, cytochromes and prolyl-hydroxylases, Cardiovasc. Res., 71, 195, 10.1016/j.cardiores.2006.04.008 · DOI · Paper page
- Semenza, 2003, Targeting HIF-1 for cancer therapy, Nat. Rev. Cancer, 3, 721, 10.1038/nrc1187 · DOI · Paper page
- Wang, 2005, Differential gene up-regulation by hypoxia-inducible factor-1α and hypoxia-inducible factor-2α in HEK293T cells, Cancer Res., 65, 3299, 10.1158/0008-5472.CAN-04-4130 · DOI · Paper page
- Harris, 2002, Hypoxia—A key regulatory factor in tumour growth, Nat. Rev. Cancer, 2, 38, 10.1038/nrc704 · DOI · Paper page
- Liao, 2007, Hypoxia: A key regulator of angiogenesis in cancer, Cancer Metastasis Rev., 26, 281, 10.1007/s10555-007-9066-y · DOI · Paper page
- Zhou, 2018, HIF-3α Promotes Metastatic Phenotypes in Pancreatic Cancer by Transcriptional Regulation of the RhoC–ROCK1 Signaling Pathway, Mol. Cancer Res., 16, 124, 10.1158/1541-7786.MCR-17-0256 · DOI · Paper page
- Joharapurkar, 2018, Prolyl hydroxylase inhibitors: A breakthrough in the therapy of anemia associated with chronic diseases, J. Med. Chem., 61, 6964, 10.1021/acs.jmedchem.7b01686 · DOI · Paper page
- Dhillon, 2019, Roxadustat: First global approval, Drugs, 79, 563, 10.1007/s40265-019-01077-1 · DOI · Paper page
- Sakashita, 2019, Hypoxia-inducible factor-prolyl hydroxylase domain inhibitors to treat anemia in chronic kidney disease, CKD-Associated Complications: Progress in the Last Half Century, Volume 198, 112
- Kim, 2015, NNC 55-0396, a T-type Ca 2+ channel inhibitor, inhibits angiogenesis via suppression of hypoxia-inducible factor-1α signal transduction, J. Mol. Med., 93, 499, 10.1007/s00109-014-1235-1 · DOI
- Zhu, 2017, Inhibition of HIF-1α by PX-478 suppresses tumor growth of esophageal squamous cell cancer in vitro and in vivo, Am. J. Cancer Res., 7, 1198
- Hideshima, 2003, Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341, Blood J. Am. Soc. Hematol., 101, 1530
- Kane, 2003, Velcade®: US FDA approval for the treatment of multiple myeloma progressing on prior therapy, Oncologist, 8, 508, 10.1634/theoncologist.8-6-508 · DOI · Paper page
- Winning, 2010, Acute hypoxia induces HIF-independent monocyte adhesion to endothelial cells through increased intercellular adhesion molecule-1 expression: The role of hypoxic inhibition of prolyl hydroxylase activity for the induction of NF-κB, J. Immunol., 185, 1786, 10.4049/jimmunol.0903244 · DOI
- Huang, 2015, Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis, Oncotarget, 6, 18590, 10.18632/oncotarget.4068 · DOI
- Oh, 2015, The histone methyltransferase inhibitor BIX01294 inhibits HIF-1α stability and angiogenesis, Mol. Cells, 38, 528, 10.14348/molcells.2015.0026 · DOI
- Park, 2017, Molecular and functional evaluation of a novel HIF inhibitor, benzopyranyl 1, 2, 3-triazole compound, Oncotarget, 8, 7801, 10.18632/oncotarget.13955 · DOI
- Lee, 2017, Synthesis and biological evaluation of kresoxim-methyl analogues as novel inhibitors of hypoxia-inducible factor (HIF)-1 accumulation in cancer cells, Bioorg. Med. Chem. Lett., 27, 3026, 10.1016/j.bmcl.2017.05.024 · DOI
- Pham, 2015, Translational impact of nanoparticle–drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer, Clin. Cancer Res., 21, 808, 10.1158/1078-0432.CCR-14-2810 · DOI · Paper page
- Esteller, 2007, Cancer epigenomics: DNA methylomes and histone-modification maps, Nat. Rev. Genet., 8, 286, 10.1038/nrg2005 · DOI · Paper page
- Jones, 2007, The epigenomics of cancer, Cell, 128, 683, 10.1016/j.cell.2007.01.029 · DOI · Paper page
- Berdasco, 2010, Aberrant epigenetic landscape in cancer: How cellular identity goes awry, Dev. Cell, 19, 698, 10.1016/j.devcel.2010.10.005 · DOI · Paper page
- Mann, 2007, Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma, Clin. Cancer Res., 13, 2318, 10.1158/1078-0432.CCR-06-2672 · DOI · Paper page
- Prince, 2012, Romidepsin for cutaneous T-cell lymphoma, Clin. Cancer Res., 18, 3509, 10.1158/1078-0432.CCR-11-3144 · DOI
- Poole, 2014, Belinostat: First global approval, Drugs, 74, 1543, 10.1007/s40265-014-0275-8 · DOI · Paper page
- Cheng, 2015, Panobinostat, a pan-histone deacetylase inhibitor: Rationale for and application to treatment of multiple myeloma, Drugs Today (Barc. Spain), 51, 491, 10.1358/dot.2015.51.8.2362311 · DOI · Paper page
- Pojani, E., and Barlocco, D. (2020). Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy. Curr. Med. Chem. · DOI
- Emerit, 2004, Neurodegenerative diseases and oxidative stress, Biomed. Pharmacother., 58, 39, 10.1016/j.biopha.2003.11.004 · DOI · Paper page
- Camelo, 2005, Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis, J. Neuroimmunol., 164, 10, 10.1016/j.jneuroim.2005.02.022 · DOI · Paper page
- Karuppagounder, 2020, The drug adaptaquin blocks ATF4/CHOP-dependent pro-death Trib3 induction and protects in cellular and mouse models of Parkinson’s disease, Neurobiol. Dis., 136, 104725, 10.1016/j.nbd.2019.104725 · DOI
- Alim, 2019, Selenium drives a transcriptional adaptive program to block ferroptosis and treat stroke, Cell, 177, 1262, 10.1016/j.cell.2019.03.032 · DOI · Paper page
- Ryu, 2003, Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway, Proc. Natl. Acad. Sci. USA, 100, 4281, 10.1073/pnas.0737363100 · DOI · Paper page
- Rroji, 2020, Epigenetic regulators of neuronal ferroptosis identify novel therapeutics for neurological diseases: HDACs, transglutaminases, and HIF prolyl hydroxylases, Neurobiol. Dis., 147, 105145, 10.1016/j.nbd.2020.105145 · DOI
- Kim, 2015, Tetrathiomolybdate inhibits mitochondrial complex IV and mediates degradation of hypoxia-inducible factor-1α in cancer cells, Sci. Rep., 5, 14296, 10.1038/srep14296 · DOI
- Rose, 2011, Inhibition of 2-oxoglutarate dependent oxygenases, Chem. Soc. Rev., 40, 4364, 10.1039/c0cs00203h · DOI · Paper page
- Sun, 2018, Exploring the inhibition mechanism on HIF-2 by inhibitor PT2399 and 0X3 using molecular dynamics simulations, J. Mol. Recognit., 31, e2730, 10.1002/jmr.2730 · DOI
- Dekker, 2009, Histone acetyl transferases as emerging drug targets, Drug Discov. Today, 14, 942, 10.1016/j.drudis.2009.06.008 · DOI · Paper page
- Delvecchio, 2013, Structure of the p300 catalytic core and implications for chromatin targeting and HAT regulation, Nat. Struct. Mol. Biol., 20, 1040, 10.1038/nsmb.2642 · DOI · Paper page
- He, Z.-X., Wei, B.-F., Zhang, X., Gong, Y.-P., Ma, L.-Y., and Zhao, W. (2020). Current development of CBP/p300 inhibitors in the last decade. Eur. J. Med. Chem., 112861. · DOI · Paper page
- Knurowski, 2019, An Open-Label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477, a First in Clinic Inhibitor of the p300/CPB Bromodomains, As Monotherapy in Patients with Advanced Haematological Malignancies, Blood, 134, 1266, 10.1182/blood-2019-124797 · doi:10.1182/blood-2019-124797
- Imayoshi, 2017, CG13250, a novel bromodomain inhibitor, suppresses proliferation of multiple myeloma cells in an orthotopic mouse model, Biochem. Biophys. Res. Commun., 484, 262, 10.1016/j.bbrc.2017.01.088 · DOI
- Zhang, 2020, Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening, Acta Pharmacol. Sin., 41, 286, 10.1038/s41401-019-0256-2 · DOI
- Jubb, 2004, Expression of vascular endothelial growth factor, hypoxia inducible factor 1α, and carbonic anhydrase IX in human tumours, J. Clin. Pathol., 57, 504, 10.1136/jcp.2003.012963 · DOI · Paper page
- Escudier, 2007, Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial, Lancet, 370, 2103, 10.1016/S0140-6736(07)61904-7 · DOI · Paper page
- Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N. Engl. J. Med., 356, 115, 10.1056/NEJMoa065044 · DOI · Paper page
- Escudier, 2007, Sorafenib in advanced clear-cell renal-cell carcinoma, N. Engl. J. Med., 356, 125, 10.1056/NEJMoa060655 · DOI · Paper page
- Hua, 2019, Targeting mTOR for cancer therapy, J. Hematol. Oncol., 12, 71, 10.1186/s13045-019-0754-1 · DOI · Paper page
- Jafari, 2014, The cellular thermal shift assay for evaluating drug target interactions in cells, Nat. Protoc., 9, 2100, 10.1038/nprot.2014.138 · DOI · Paper page
- 1948, Zwischenmolekulare Energiewanderung und Fluoreszenz, Ann. Phys., 437, 55, 10.1002/andp.19484370105 · DOI · Paper page
- Lakowicz, 2009, Modification of single molecule fluorescence near metallic nanostructures, Laser Photonics Rev., 3, 221, 10.1002/lpor.200810035 · doi:10.1002/lpor.200810035
- Bastiaens, 1999, Fluorescence lifetime imaging microscopy: Spatial resolution of biochemical processes in the cell, Trends Cell Biol., 9, 48, 10.1016/S0962-8924(98)01410-X · DOI · Paper page
- Majoul, 2002, Fluorescence resonance energy transfer analysis of protein–protein interactions in single living cells by multifocal multiphoton microscopy, Rev. Mol. Biotechnol., 82, 267, 10.1016/S1389-0352(01)00042-3 · DOI
- Clayton, 2004, Graphical representation and multicomponent analysis of single-frequency fluorescence lifetime imaging microscopy data, J. Microsc., 213, 1, 10.1111/j.1365-2818.2004.01265.x · DOI · Paper page
- Wotzlaw, 2004, Visualization of the three-dimensional organization of hypoxia-inducible factor-1 alpha and interacting cofactors in subnuclear structures, Biol. Chem., 385, 231
- Wotzlaw, 2007, Optical analysis of the HIF-1 complex in living cells by FRET and FRAP, FASEB J., 21, 700, 10.1096/fj.06-6280com · DOI
- Frede, 2008, Imaging of the hypoxia-inducible factor pathway: Insights into oxygen sensing, Eur. Respir. J., 32, 210, 10.1183/09031936.00013408 · DOI
- Konietzny, 2009, Molecular Imaging: Into In Vivo Interaction of HIF-1α and HIF-2α with ARNT, Ann. N. Y. Acad. Sci., 1177, 74, 10.1111/j.1749-6632.2009.05029.x · DOI
- Hoffmann, 2017, Optical analysis of cellular oxygen sensing, Exp. Cell Res., 356, 122, 10.1016/j.yexcr.2017.03.009 · DOI
- Frangioni, 2003, In vivo near-infrared fluorescence imaging, Curr. Opin. Chem. Biol., 7, 626, 10.1016/j.cbpa.2003.08.007 · DOI · Paper page
- Iglesias, 2009, A novel BRET-based genetically encoded biosensor for functional imaging of hypoxia, Biosens. Bioelectron., 24, 3126, 10.1016/j.bios.2009.04.013 · DOI
- Kuchimaru, 2016, A novel injectable BRET-based in vivo imaging probe for detecting the activity of hypoxia-inducible factor regulated by the ubiquitin-proteasome system, Sci. Rep., 6, 34311, 10.1038/srep34311 · DOI
- Xiong, 2012, Self-luminescing BRET-FRET near-infrared dots for in vivo lymph-node mapping and tumour imaging, Nat. Commun., 3, 1193, 10.1038/ncomms2197 · DOI · Paper page
- Nikooharf, 2020, Development of a Recombinant Monospecific Anti-PLGF Bivalent Nanobody and Evaluation of it in Angiogenesis Modulation, Mol. Biotechnol., 62, 580, 10.1007/s12033-020-00275-7 · DOI
- Campochiaro, 2015, Molecular pathogenesis of retinal and choroidal vascular diseases, Prog. Retin. Eye Res., 49, 67, 10.1016/j.preteyeres.2015.06.002 · DOI · Paper page
- Stumpf, C., Wimmer, T., Lorenz, B., and Stieger, K. (2020). Creation of different bioluminescence resonance energy transfer based biosensors with high affinity to VEGF. PLoS ONE, 15. · DOI
- Robers, 2015, Target engagement and drug residence time can be observed in living cells with BRET, Nat. Commun., 6, 1, 10.1038/ncomms10091 · DOI · Paper page
- Kuo, 1999, In Vivo Cross-Linking and Immunoprecipitation for Studying Dynamic Protein: DNA Associations in a Chromatin Environment, Methods, 19, 425, 10.1006/meth.1999.0879 · DOI · Paper page
- Orlando, 2000, Mapping chromosomal proteins in vivo by formaldehyde-crosslinked-chromatin immunoprecipitation, Trends Biochem. Sci., 25, 99, 10.1016/S0968-0004(99)01535-2 · DOI · Paper page
- Turner, 2003, Immunoprecipitation of native chromatin: NChIP, Methods, 31, 76, 10.1016/S1046-2023(03)00090-2 · DOI · Paper page
- Collas, 2010, The current state of chromatin immunoprecipitation, Mol. Biotechnol., 45, 87, 10.1007/s12033-009-9239-8 · DOI · Paper page
- Dolk, 2005, Induced refolding of a temperature denatured llama heavy-chain antibody fragment by its antigen, Proteins Struct. Funct. Bioinform., 59, 555, 10.1002/prot.20378 · DOI
- Hu, 2017, Nanobody-based delivery systems for diagnosis and targeted tumor therapy, Front. Immunol., 8, 1442, 10.3389/fimmu.2017.01442 · DOI · Paper page
- Chanier, T., and Chames, P. (2019). Nanobody engineering: Toward next generation immunotherapies and immunoimaging of cancer. Antibodies, 8. · DOI
- Schoonooghe, 2012, Novel applications of nanobodies for in vivo bio-imaging of inflamed tissues in inflammatory diseases and cancer, Immunobiology, 217, 1266, 10.1016/j.imbio.2012.07.009 · DOI
- Krasniqi, 2017, Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin lymphoma, Mol. Cancer Ther., 16, 2828, 10.1158/1535-7163.MCT-17-0554 · DOI
- Warnders, 2017, Human epidermal growth factor receptor 3–specific tumor uptake and biodistribution of 89Zr-MSB0010853 visualized by real-time and noninvasive PET imaging, J. Nucl. Med., 58, 1210, 10.2967/jnumed.116.181586 · DOI
- Balhuizen, 2017, A nanobody-based tracer targeting DPP6 for non-invasive imaging of human pancreatic endocrine cells, Sci. Rep., 7, 1, 10.1038/s41598-017-15417-2 · DOI
- Massa, 2016, Sortase A-mediated site-specific labeling of camelid single-domain antibody-fragments: A versatile strategy for multiple molecular imaging modalities, Contrast Media Mol. Imaging, 11, 328, 10.1002/cmmi.1696 · DOI
- Mann, 2019, Nanobody-Conjugated Nanotubes for Targeted Near-Infrared In Vivo Imaging and Sensing, Angew. Chem. Int. Ed., 58, 11469, 10.1002/anie.201904167 · DOI
Cited by
Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target
Infantino, V., Santarsiero, A., Convertini, P., Todisco, S., & Iacobazzi, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115703 · Cited by 499
Revisiting the HIF switch in the tumor and its immune microenvironment.
Cowman, S. J., & Koh, M. Y. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2021.10.004 · Cited by 256
Prevention of Post-Operative Adhesions: A Comprehensive Review of Present and Emerging Strategies
Fatehi Hassanabad, A., Zarzycki, A. N., Jeon, K., Dundas, J. A., Vasanthan, V., Deniset, J. F., & Fedak, P. W. M. (2021) · Biomolecules · doi:10.3390/biom11071027 · Cited by 178
“Regarding HIF inhibitors, the use of many is dampened by their off-target effects, affecting different pathways in DNA replication, cell division, or cell signaling [220].”
BackgroundAssociations between HIFs and tumor immune checkpoints: mechanism and therapy
Liu, J., Jiang, Y., Chen, L., Qian, Z., & Zhang, Y. (2024) · Discover Oncology · doi:10.1007/s12672-023-00836-7 · Cited by 13
“In a similar vein, a range of anti-cancer medications, including those that block the PI-3 K-mTOR pathway, histone deacetylases (HDAC), or topoisomerase, exhibit indirect impacts and varying degrees of effectiveness in reducing the production of and activation of HIF-1/2α [159].”
Background
Metadata
- Authors
- Schönberger, T., Fandrey, J., & Prost-Fingerle, K.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-01-05
- Volume
- 13
- Issue
- 1
- Pages
- 159
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3118574324
- Cited by
- 38
- References
- 39
- FWCI
- 2.47
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ways into Understanding HIF Inhibition. https://app.cochat.ai/papers/10.3390/cancers13010159
- The paper
- Schönberger, T., Fandrey, J., & Prost-Fingerle, K. (2021). Ways into Understanding HIF Inhibition. Cancers. https://doi.org/10.3390/cancers13010159
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.